Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA

Rein Therapeutics, Inc.

Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.
Standby Equity Purchase Agreement: up to $15M over 36 months; shares sold at 96% of lowest 3-day VWAP.
Floor price set at $0.28 per share; Yorkville may require share issuance at lower of 115% of VWAP or 95% of lowest 7-day VWAP.
Commitment fee of $300k paid as 213,099 shares plus $25k structuring fees; Exchange Cap limited to 19.9% of outstanding shares.
Proceeds used for general corporate purposes; shares registered on Form S-3 (File No. 333-287342).

item 1.01item 2.03item 3.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.